← Eichor
Condition: Plaque Psoriasis Patients Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Plaque Psoriasis Patients

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Phase 2 Study of HB0017 in Psoriasis Patients
Phase 2 · 18 location(s) · Huabo Biopharm Co., Ltd. · NCT06592274Immune Infiltrate Analysis of Psoriasis Skin During Therapy With Anti-interleukin 23 (IL-23)
Phase N/A · 1 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT06792487A Phase 3 Clinical Study of QL2106 Injection
Phase 3 · 1 location(s) · Qilu Pharmaceutical Co., Ltd. · NCT07511647A Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLD
Phase N/A · 3 location(s) · Novartis Pharmaceuticals · NCT07683065Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques
Phase 1 · 3 location(s) · SFA Therapeutics · NCT05642182ROLL'YN-UST: an Observational Study in Patients Treated by Steqeyma®, an Ustekinumab Biosimilar
Phase N/A · 1 location(s) · Celltrion HealthCare France · NCT06997055Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis
Phase 2 · 36 location(s) · Oruka Therapeutics, Inc. · NCT07290569Carotid Ultrasound-Based Strategy for Primary Prevention of Cardiovascular Events in Inflammatory Rheumatic Disease (PRE
Phase 4 · 17 location(s) · Instituto de Investigación Marqués de Valdecilla · NCT07611747To Check Comparison of Apremilast and Methotrexate Efficacy in Patients With Moderate to Severe Plaque Psoriasis Present
EARLY_Phase 1 · 1 location(s) · Syeda Sana Zaman · NCT07337434A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in
Phase N/A · 1 location(s) · Almirall, S.A. · NCT06030076Modifying PEST for Psoriatic Arthritis Screening
NA · 30 location(s) · Novartis Pharmaceuticals · NCT06382051Outcomes With Treatment and Withdraw of Ixekizumab in Patients With Plaque Psoriasis
Phase 4 · 1 location(s) · Singapore General Hospital · NCT04537689Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis
Phase 3 · 46 location(s) · Beijing InnoCare Pharma Tech Co., Ltd. · NCT06842199Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque
Phase N/A · 81 location(s) · AbbVie · NCT07039110A Study to Evaluate the Efficacy and Safety of CS32582 in Participants With Moderate to Severe Plaque Psoriasis
Phase 1/Phase 2 · 11 location(s) · Chipscreen Biosciences, Ltd. · NCT07129382A Phase 2 Study of ZL-1102 in Patients With Chronic Plaque Psoriasis
Phase 2 · 10 location(s) · Zai Lab (Hong Kong), Ltd. · NCT06380907Efficacy and Safety of ICP-332 Versus Placebo in Participants With Moderate to Severe Plaque Psoriasis
Phase 2 · 1 location(s) · Beijing InnoCare Pharma Tech Co., Ltd. · NCT07251998SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)
Phase N/A · 8 location(s) · Leiden University Medical Center · NCT07021495Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis
Phase 2 · 34 location(s) · Oruka Therapeutics, Inc. · NCT07474792A Study of Persistence to Guselkumab Treatment in Participants With Moderate-to-Severe Plaque Psoriasis in Romania
Phase N/A · 19 location(s) · Janssen Research & Development, LLC · NCT07582783Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis
Phase 4 · 1 location(s) · Psoriasis Treatment Center of Central New Jersey · NCT03827876Clinical Study on the Medical Devices PROXERA PSOMED 20 and PROXERA PSOMED 40 for the Treatment of Plaque Psoriasis and
NA · 1 location(s) · ICIM International S.r.l. · NCT07545902Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in
Phase N/A · 2 location(s) · Bristol-Myers Squibb · NCT06258668A Study to Evaluate Efficacy and Safety of IBI112 in Adolescent Participants With Moderate to Severe Plaque Psoriasis
Phase 3 · 1 location(s) · Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · NCT07265284
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.